Barclays
HRMY icon

Barclays’s Harmony Biosciences HRMY Stock Holding History

Barclays’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.89M Sell
51,860
-10,860
-17% -$343K ﹤0.01% 2371
2026
Q1 		$1.76M Sell
62,720
-52,754
-46% -$1.73M ﹤0.01% 2428
2025
Q4 		$4.32M Buy
115,474
+3,960
+4% +$130K ﹤0.01% 2326
2025
Q3 		$3.07M Sell
111,514
-15,599
-12% -$537K ﹤0.01% 2542
2025
Q2 		$4.02M Buy
127,113
+43,823
+53% +$1.41M ﹤0.01% 2307
2025
Q1 		$2.76M Sell
83,290
-17,582
-17% -$630K ﹤0.01% 2383
2024
Q4 		$3.47M Buy
100,872
+24,010
+31% +$825K ﹤0.01% 2463
2024
Q3 		$3.07M Buy
76,862
+40,416
+111% +$1.42M ﹤0.01% 2497
2024
Q2 		$1.1M Sell
36,446
-13,498
-27% -$406K ﹤0.01% 2543
2024
Q1 		$1.68M Sell
49,944
-21,314
-30% -$684K ﹤0.01% 2721
2023
Q4 		$2.3M Buy
71,258
+37,069
+108% +$1.03M ﹤0.01% 2797
2023
Q3 		$1.12M Buy
34,189
+4,461
+15% +$155K ﹤0.01% 2259
2023
Q2 		$1.05M Buy
29,728
+750
+3% +$25.9K ﹤0.01% 2274
2023
Q1 		$946K Buy
28,978
+5,719
+25% +$260K ﹤0.01% 2770
2022
Q4 		$1.28M Sell
23,259
-881
-4% -$48.4K ﹤0.01% 2600
2022
Q3 		$1.07M Buy
24,140
+1,383
+6% +$67.5K ﹤0.01% 2182
2022
Q2 		$1.11M Sell
22,757
-4,422
-16% -$199K ﹤0.01% 2266
2022
Q1 		$1.32M Buy
+27,179
New +$1.11M ﹤0.01% 2188

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's HRMY Position: Q2 2026 in Review

Barclays reduced its Harmony Biosciences (HRMY) stake by 17% in Q2 2026, selling an estimated $343K and leaving 51,860 shares worth $1.89M. The position accounts for ﹤0.01% of the portfolio, ranked #2371.

Barclays first reported a position in HRMY in Q1 2022 and has held it in 18 quarters since. The position peaked at $4.32M in Q4 2025. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Barclays held 51,860 shares of Harmony Biosciences worth $1.89M as of Q2 2026.
  • Barclays sold 10,860 Harmony Biosciences shares in Q2 2026, an estimated $343K.
  • Harmony Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2371 holding.
  • Barclays first reported a position in Harmony Biosciences in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Harmony Biosciences position peaked at $4.32M in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.